Qiagen Gestion

Gestion contrôle des critères 4/4

Le PDG Qiagen est Thierry Bernard, nommé en Oct2019, a un mandat de 5.08 ans. La rémunération annuelle totale est $ 1.99M, composée du salaire de 49.1% et des bonus 50.9%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de € 13.07M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.8 ans et 9.6 ans.

Informations clés

Thierry Bernard

Directeur général

US$2.0m

Rémunération totale

Pourcentage du salaire du PDG	49.1%
Durée du mandat du directeur général	5.1yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	6.8yrs
Durée moyenne du mandat des membres du conseil d'administration	9.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Thierry Bernard a-t-elle évolué par rapport aux bénéfices de Qiagen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$93m
Jun 30 2024	n/a	n/a	US$73m
Mar 31 2024	n/a	n/a	US$337m
Dec 31 2023	US$2m	US$979k	US$341m
Sep 30 2023	n/a	n/a	US$332m
Jun 30 2023	n/a	n/a	US$337m
Mar 31 2023	n/a	n/a	US$353m
Dec 31 2022	US$10m	US$950k	US$423m
Sep 30 2022	n/a	n/a	US$488m
Jun 30 2022	n/a	n/a	US$539m
Mar 31 2022	n/a	n/a	US$563m
Dec 31 2021	US$2m	US$900k	US$513m
Sep 30 2021	n/a	n/a	US$311m
Jun 30 2021	n/a	n/a	US$480m
Mar 31 2021	n/a	n/a	US$449m
Dec 31 2020	US$2m	US$900k	US$359m
Sep 30 2020	n/a	n/a	US$191m
Jun 30 2020	n/a	n/a	US$14m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$650k	-US$41m

Rémunération vs marché: La rémunération totale de Thierry ($USD 1.99M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 3.58M ).

Rémunération et revenus: La rémunération de Thierry a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Thierry Bernard (60 yo)

5.1yrs

Titularisation

US$1,991,874

Compensation

Mr. Thierry Bernard serves as Director of Neogen Corporation since November 01, 2024. He has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board s...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Thierry Bernard	CEO, MD & Member of Management Board	5.1yrs	US$1.99m	0.14% € 13.1m
Roland Sackers	CFO, MD & Member of Management Board	20.8yrs	US$1.07m	0.19% € 17.1m
Antonio Santos	Senior VP & Head of Global Operations	2.6yrs	pas de données	pas de données
John Gilardi	Vice President of Corporate Communications & Investor Relations	14.1yrs	pas de données	pas de données
Stephany Foster	Senior VP & Head of Human Resources	5.1yrs	pas de données	pas de données
Thomas Schweins	Senior Vice President of Life Science Business Area	6.8yrs	pas de données	pas de données
Thomas Theuringer	Senior Director & Head of External Communications	no data	pas de données	pas de données
Jean-Pascal Viola	Senior VP & Head of Corporate Strategy and Business Development	9.5yrs	pas de données	pas de données
Jonathan Sheldon	Senior VP & Head of the QIAGEN Digital Insights Business Area	6.8yrs	pas de données	pas de données
Fernando Beils	Senior VP & Head of the Molecular Diagnostics Business Area	no data	pas de données	pas de données
Nitin Sood	Senior VP & Head of the Life Sciences Business Area	no data	pas de données	pas de données

6.8yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de QIA est chevronnée et expérimentée (6.8 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Stephen Rusckowski	Independent Member of Supervisory Board	1.6yrs	US$46.07k	0.000010% € 905.1
Metin Colpan	Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board	20.8yrs	US$86.50k	0.080% € 7.2m
Elizabeth Tallett	Independent Member of the Supervisory Board	13.4yrs	US$101.50k	0.022% € 2.0m
Eva Pisa	Independent Member of the Supervisory Board	2.4yrs	US$68.50k	pas de données
Lawrence Rosen	Independent Chairman of Supervisory Board	11.4yrs	US$188.50k	0.0067% € 607.3k
Toralf Haag	Independent Member of the Supervisory Board	3.8yrs	US$82.50k	0.0012% € 106.8k
Elaine Mardis	Independent Member of the Supervisory Board	10.4yrs	US$79.50k	0.0018% € 166.5k
Peter Kaspar	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Ross Levine	Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board	8.8yrs	US$68.50k	0.0075% € 681.5k
Patrice Nordmann	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Neville Sanjana	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Sarah Polonius-Teichmann	Member of the Scientific Advisory Board	no data	pas de données	pas de données

9.6yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de QIA sont considérés comme expérimentés (ancienneté moyenne 9.6 ans).

Qiagen Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V., Annual General Meeting, Jun 21, 2024

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Board Member recently sold €204k worth of stock

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

Recent updates

Qiagen Collaborates with McGill University to Advance Microbiome Research

Third quarter 2024 earnings released: EPS: US$0.44 (vs US$0.35 in 3Q 2023)

Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024

QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics

QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment

QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications

Qiagen N.V. to Report Q3, 2024 Results on Nov 06, 2024

QIAGEN N.V. Launches QIAcuityDx Digital PCR System for Clinical Testing in Oncology

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care

Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine

QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret

Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results

Qiagen N.V., Annual General Meeting, Jun 21, 2024

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.39 in 1Q 2023)

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Full year 2023 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022)

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022)

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued after recent price drop

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings: EPS misses analyst expectations

Board Member recently sold €204k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

Now 20% undervalued

Now 21% undervalued

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Now 21% undervalued after recent price drop

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

Price target increased to €50.58

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency